6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
申请人:Briner Karin
公开号:US20080214520A1
公开(公告)日:2008-09-04
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT
2C
receptor agonists for the treatment of 5-HT
2C
associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R
6
is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.
The present invention relates to a compound of formula: (I) or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection such as HIV using the same.
COBALT COMPLEX, METHOD FOR MANUFACTURING SAME, AND METHOD FOR MANUFACTURING COBALT-CONTAINING THIN FILM
申请人:TOSOH CORPORATION
公开号:US20220017553A1
公开(公告)日:2022-01-20
To provide a cobalt complex which is liquid at room temperature, useful for producing a cobalt-containing thin film under conditions without using an oxidizing gas.
A cobalt complex represented by the following formula (1):
L
1
-Co-L
2
(1)
wherein L
1
and L
2
represent a unidentate amide ligand of the following formula (A), a bidentate amide ligand of the following formula (B) or a hetero atom-containing ligand of the following formula (C):
wherein R
1
and R
2
represent a C
1-6
alkyl group or a tri(C
1-6
alkyl)silyl group, and the wave line represents a binding site to the cobalt atom;
wherein R
3
represents a tri(C
1-6
alkyl)silyl group, R
4
and R
5
represent a C
1-4
alkyl group, and X represents a C
1-6
alkylene group;
wherein R
6
and R
8
represent a C
1-6
alkyl group, R
7
represents a hydrogen atom or a C
1-4
alkyl group, Y represents an oxygen atom or NR
9
, Z represents an oxygen atom or NR
10
, and R
9
and R
10
independently represent a C
1-6
alkyl group.
utilized as an efficient heterogeneous recyclable catalyst for Knoevenagel condensationbetween poorly reactive β-diketones and aldehydes under solvent-free conditions. This protocol also works well with more reactive β-ketoesters. The condensation is efficient, clean, and mild. The scope and generality of the Knoevenagel condensation were investigated. The procedure led only to the Knoevenagel product,
(ACD). We report herein the synthesis and structure-activity relationships (SARs) of a series of benzisoxazole compounds as orallyactive hepcidin production inhibitors. The optimization study of multi kinase inhibitor 1 led to a potent and bioavailable hepcidin production inhibitor 38 (DS79182026), which showed serum hepcidin lowering effects in a mouse IL-6 induced acute inflammatory model.